Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Immunic, Inc.NASDAQ: IMUX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $33K fell 23.3% year over year, behind the +4.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.4% from the prior quarter. Over 3 fiscal years it compounded at +29.7% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -23.3% toward the trailing-twelve-month pace of +4.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 168K USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +18.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 168K | +25.4% |
| FY2024 | 2024-12-31 | 134K | +20.7% |
| FY2023 | 2023-12-31 | 111K | +44.2% |
| FY2022 | 2022-12-31 | 77K | -9.4% |
| FY2021 | 2021-12-31 | 85K | — |
Depreciation & Amortization vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 depreciation & amortization of $158K is the 7th largest of the 9 companies compared; the peer median is $2.04M.
- Its year-over-year change of +4.6% is the 2nd highest of 8, against a peer median of -18.4%.
- Over three fiscal years its annual growth of +29.7% compares with a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.74M | -13.3% | +13.9% | 3.0% | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.46M | -18.2% | +56.9% | 127.4% |
| LTM Mar 2026 | $3.86M | -37.8% | -3.9% | — | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.21M | +8.3% | +36.2% | — |
| LTM Mar 2026 | $960K | -46.5% | +26.8% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $131K | -84.0% | -41.1% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding IMUX) | $2.04M | -18.4% | +13.9% | 31.5% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| Deferred Income Tax | 4.33M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.95M | 7.93M | 7.1M | 8.53M | 8.86M |
| Change in Working Capital | (9.28M) | 9.53M | 15.05M | 564K | 1.84M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 176K | 799K | 817K | 3.15M | 1.24M |
| Other Working Capital | (9.46M) | 8.73M | 14.23M | (2.58M) | 601K |
| Other Non-Cash Items | 8.63M | 37.73M | 523K | 6.52M | 497K |
| Operating Cash Flow | (83.23M) | (65.14M) | (70.83M) | (84.77M) | (85.81M) |
| Capital Expenditures | (67K) | (112K) | (334K) | (264K) | (161K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (9.63M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 9.8M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (67K) | (9.74M) | 9.46M | (264K) | (161K) |
| Debt Repayment | 0 | 0 | 0 | 74.27M | 0 |
| Common Stock Issued | 42.75M | 39.58M | 853K | 191K | 65.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 92K | 187K | 180K | 77K | 0 |
| Financing Cash Flow | 42.84M | 95.76M | 1.03M | 74.54M | 65.58M |
| Effect of Forex Changes | (130K) | (993K) | 262K | (517K) | 205K |
| Net Change in Cash | (40.59M) | 19.88M | (60.07M) | (11.01M) | (20.19M) |
| Free Cash Flow | (83.3M) | (65.26M) | (71.16M) | (85.03M) | (85.97M) |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.